logo

Aeterna Zentaris Inc (AEZS)



Trade AEZS now with
  Date
  Headline
6/3/2021 8:13:53 AM Aeterna Zentaris Reports Final Settlement Of Previously Disclosed Class-Action Lawsuit
5/17/2021 8:23:17 AM Aeterna Reports Start Of Preclinical Development Of Macimorelin At The University Of Queensland
3/25/2021 8:10:12 AM Aeterna Zentaris Q4 Total Revenue $2.4 Mln Vs $0.02 Mln Last Year
3/11/2021 8:09:06 AM Aeterna Zentaris Initiate Preclinical Program For Potential Treatment Of Primary Hypoparathyroidism
12/7/2020 8:11:36 AM Aeterna Zentaris Enters Exclusive Licensing Agreement With Consilient Health, Ltd.
11/16/2020 8:15:40 AM Aeterna Zentaris Amends License Agreement With Novo Nordisk
11/6/2020 8:40:12 AM Aeterna Zentaris Q3 Consolidated Net Loss $1.1 Mln Or $0.02 Per Basic Share
9/16/2020 8:19:17 AM Aeterna Zentaris Expects Pivotal Phase 3 Safety, Efficacy Study AEZS-130-P02 To Begin In Q1'21
6/25/2020 8:17:35 AM Aeterna Zentaris Enters Exclusive Distribution And Related Quality Agreement With Megapharm
6/8/2020 8:12:53 AM Aeterna Zentaris Regains Compliance With Minimum Bid Price For Continued Listing On Nasdaq Capital Market
4/6/2020 9:12:25 AM Aeterna Zentaris Announces Positive Results For First Pediatric Study Of Macimorelin
1/27/2020 8:39:05 AM Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement For Continued Listing
3/29/2012 10:58:40 AM RBC Capital Markets Is Increasing AEterna Zentaris Inc (AEZS) Q4 12 Rev. Estimate To 10.8 M From 10.2 M
3/29/2012 10:57:57 AM RBC Capital Markets Is Increasing AEterna Zentaris Inc (AEZS) Q3 12 Rev. Estimate To 13.7 M From 13.5 M